News
Sanofi and Regeneron eye Libtayo challenge to Keytruda in fi...
Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe conte
